Insight

Osimertinib could change the standard of care for EGFR-mutant NSCLC

Photo taken from fiercepharma.com

Jul 12, 2024, 23:07

Osimertinib could change the standard of care for EGFR-mutant NSCLC

Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X:

“Osimertinib could change the standard of care for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC).

The LAURA trial showed that osimertinib improves progression-free survival (PFS) in patients with unresectable NSCLC, reducing the risk of progression or death by 84% vs. placebo.

The median PFS was 39.1 months vs. 5.6 months.

The most common adverse events were radiation pneumonitis, diarrhea, and rash.”

For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines

Source: Iván R. González/X

Ángeles Puebla Hospital cancer Comprehensive Oncology Center EGFR-mutant NSCLC Iván R. González LAURA trial non small cell lung cancer OncoDaily Oncology osimertinib progression-free survival unresectable NSCLC

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage